Arcus Biosciences, Inc. Cash and Cash Equivalents, Period Increase (Decrease)
Arcus Biosciences, Inc. (RCUS) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$27.36 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-05.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2019-03-05
- Arcus Biosciences, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-12-31 was -$3.83M, a 104.77% decline year-over-year.
- Arcus Biosciences, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-09-30 was -$95.11M.
- Arcus Biosciences, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-06-30 was -$28.12M.
- Arcus Biosciences, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-03-31 was $99.69M.
- Arcus Biosciences, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2018 was -$27.36M, a 182.25% decline from fiscal 2017.
- Arcus Biosciences, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $33.27M, a 81.83% increase from fiscal 2016.
- Arcus Biosciences, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2016 was $18.30M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2018-12-31 | -$3.83M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-05 | -$98.93M derived: sum of 2 quarters · filed 2019-03-05 | -$127.05M derived: sum of 3 quarters · filed 2019-03-05 | -$27.36M 10-K · filed 2019-03-05 |
| 2018-09-30 | -$95.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | -$123.23M derived: sum of 2 quarters · filed 2018-11-08 | -$23.54M 10-Q · filed 2018-11-08 | $56.58M derived: sum of 4 quarters · filed 2019-03-05 |
| 2018-06-30 | -$28.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | $71.57M 10-Q · filed 2018-08-06 | $151.69M derived: sum of 3 quarters · filed 2019-03-05 | $140.38M derived: sum of 4 quarters · filed 2019-03-05 |
| 2018-03-31 | $99.69M 10-Q · filed 2018-05-09 | $179.81M derived: sum of 2 quarters · filed 2019-03-05 | $168.50M derived: sum of 3 quarters · filed 2019-03-05 | $159.02M derived: sum of 4 quarters · filed 2019-03-05 |
| 2017-12-31 | $80.12M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-05 | $68.81M derived: sum of 2 quarters · filed 2019-03-05 | $59.33M derived: sum of 3 quarters · filed 2019-03-05 | $33.27M 10-K · filed 2019-03-05 |
| 2017-09-30 | -$11.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | -$20.79M derived: sum of 2 quarters · filed 2018-11-08 | -$46.85M 10-Q · filed 2018-11-08 | |
| 2017-06-30 | -$9.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | -$35.54M 10-Q · filed 2018-08-06 | ||
| 2017-03-31 | -$26.06M 10-Q · filed 2018-05-09 | |||
| 2016-12-31 | $18.30M 10-K · filed 2019-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |